On October 28, 2025, the Chengdu Enterprise Innovation and Development Conference was held in Chengdu. Biokin Pharmaceutical was simultaneously selected for the "2025 Chengdu Top 100 Enterprises", "2025 Chengdu Top 100 Manufacturing Enterprises", and "2025 Chengdu Top 100 Private Enterprises" lists, demonstrating its representative status in the pharmaceutical and healthcare sector.

As a high-tech enterprise focusing on the R&D and manufacturing of biopharmaceuticals, Biokin Pharmaceutical has consistently increased its R&D investment in recent years, achieving a series of breakthrough progress in areas such as innovative drugs and high-end formulations. This inclusion in the Top 100 lists not only reflects the strong development momentum of Chengdu's biopharmaceutical industry but also signifies full recognition of the company's comprehensive strength.

The 2025 Chengdu Top 100 Enterprises list indicates that the overall threshold for inclusion has risen further, reaching a record high. Innovative enterprises represented by Biokin Pharmaceutical are actively driving industrial transformation through technological upgrades. Moving forward, the company will leverage Chengdu's favorable industrial ecosystem to accelerate the translation of innovative achievements into practical outcomes, injecting new momentum into the high-quality development of the regional economy.